BioNTech and DualityBio announce topline results of the DYNASTY-Breast02 Global Phase 3 clinical trial evaluating Trastuzumab Pamirtecan in HR+ / HER2-low metastatic breast cancer.
BioNTech and DualityBio announce topline results of the DYNASTY-Breast02 Global Phase 3 clinical trial evaluating Trastuzumab Pamirtecan in HR+ / HER2-low metastatic breast cancer.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in